Areas of Expertise

  • Immunology
  • Molecular biology
  • Drug development
  • Reproductive biology
  • Gynaecological cancer

Publications

  1. & Therapeutic Development and the Evolution of Precision Medicine. In Nanoscience and Nanotechnology for Human Health. (pp. 359-378).
  2. & Antibody–drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment. Interface Focus 6(6), 20160054
  3. Mevalonate Biosynthesis Intermediates Are Key Regulators of Innate Immunity in Bovine Endometritis. The Journal of Immunology 196(2), 823-831.
  4. & Ovarian steroids do not impact bovine endometrial cytokine/chemokine responses to E. coli or LPS in vitro. Reproduction
  5. et. al. SOCS genes expression during physiological and perturbed implantation in bovine endometrium. Reproduction

See more...

Teaching

  • PM-132 Eukaryotic Cell Biology

    This module will provide a broad introduction to fundamental concepts in Eukaryotic cell biology investigating the origins of the cell, cell structure and specialised cells and cells in disease. There will be a general focus on human cells throughout with reference to other organisms when needed. Students will gain practical experience in identification, differentiation of cells from different human and animal species.

  • PM-132C Bioleg Celloedd Ewcaryotig

    Bydd y modiwl hwn yn darparu cyflwyniad bras i gysyniadau sylfaenol ym maes bioleg celloedd Ewcaryotig, gan ymchwilio i darddiad y gell, strwythur y gell a chelloedd arbenigol a chelloedd mewn clefyd. Bydd ffocws cyffredinol ar gelloedd dynol drwy gydol y modiwl, gan gyfeirio at organebau eraill yn ôl yr angen. Bydd myfyrwyr yn cael profiad ymarferol o nodi celloedd, gwahaniaethu rhwng gwahanol gelloedd dynol a rhywogaethau o anifeiliaid.

  • PMNM04 Nanomedicines and Therapeutics

    The module will explore the history and development of molecular medicines. Using landmark technology and chemical development phases, the traditional small chemical entities using in molecular medicine will be outlined, using drugs such as taxols and tamoxifen as exemplars. The common target oncology and non oncology disorders will outlined and their respective targets for such medicines detailed alongside drug modes of action and delivery (IV and oral). Further exploration of targeted nanoparticle delivery, from early first generation drugs such as Abraxane to second generation biologically targeted SMART delivery systems, will expand the knowledge to future molecular medicines such as antibody drug conjugates and kinase inhibitors. Excitingly the module will include guest lectures from industry and clinicians, covering the spectrum of drug development to delivery and clinical considerations.